B. Venugopal

1.7k total citations
48 papers, 862 citations indexed

About

B. Venugopal is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, B. Venugopal has authored 48 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in B. Venugopal's work include Renal cell carcinoma treatment (12 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Economic and Financial Impacts of Cancer (5 papers). B. Venugopal is often cited by papers focused on Renal cell carcinoma treatment (12 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Economic and Financial Impacts of Cancer (5 papers). B. Venugopal collaborates with scholars based in United States, United Kingdom and France. B. Venugopal's co-authors include T.R. Jeffry Evans, Susan A. Slaugenhaupt, Cyntia Curcio‐Morelli, T. D. Luckey, Marsha F. Browning, Steven U. Walkley, Florie A. Charles, Jing Zhou, Takeshi Yuasa and John C. Kennedy and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of the New York Academy of Sciences.

In The Last Decade

B. Venugopal

42 papers receiving 844 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Venugopal United States 15 295 256 142 135 123 48 862
Zhixian Hu United States 14 597 2.0× 68 0.3× 86 0.6× 322 2.4× 72 0.6× 20 1.2k
Cinzia Bottino Italy 15 543 1.8× 50 0.2× 256 1.8× 41 0.3× 133 1.1× 16 1.1k
Germano Baj Italy 10 279 0.9× 114 0.4× 34 0.2× 155 1.1× 30 0.2× 13 1.1k
Carolin Thomas Germany 12 297 1.0× 33 0.1× 98 0.7× 52 0.4× 36 0.3× 16 803
Li Dong China 14 339 1.1× 36 0.1× 31 0.2× 119 0.9× 75 0.6× 26 725
Kiyoshi Inageda Japan 18 300 1.0× 275 1.1× 125 0.9× 65 0.5× 12 0.1× 22 808
Hasan Mahmud Germany 25 662 2.2× 152 0.6× 29 0.2× 57 0.4× 480 3.9× 52 1.6k
Manfred Wirth Germany 22 268 0.9× 72 0.3× 50 0.4× 35 0.3× 562 4.6× 45 1.6k
Mei Liang China 16 472 1.6× 33 0.1× 19 0.1× 52 0.4× 139 1.1× 43 1.1k
Luca Troncone United States 12 323 1.1× 21 0.1× 20 0.1× 58 0.4× 156 1.3× 17 802

Countries citing papers authored by B. Venugopal

Since Specialization
Citations

This map shows the geographic impact of B. Venugopal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Venugopal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Venugopal more than expected).

Fields of papers citing papers by B. Venugopal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Venugopal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Venugopal. The network helps show where B. Venugopal may publish in the future.

Co-authorship network of co-authors of B. Venugopal

This figure shows the co-authorship network connecting the top 25 collaborators of B. Venugopal. A scholar is included among the top collaborators of B. Venugopal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Venugopal. B. Venugopal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kumar, Pramod, et al.. (2024). Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report. American Journal of Transplantation. 24(6). 1087–1090. 10 indexed citations
3.
Sharma, Ashish, B. Venugopal, Jens Bedke, et al.. (2024). 1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC). Annals of Oncology. 35. S1015–S1015. 3 indexed citations
4.
Rini, Brian I., Laurence Albigès, Mauricio Burotto, et al.. (2024). LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC). Annals of Oncology. 35. S1262–S1263. 3 indexed citations
5.
Manivasakam, P., et al.. (2023). Autophagy: An Emerging Target for Developing Effective Analgesics. ACS Omega. 8(10). 9445–9453. 7 indexed citations
6.
Freedland, Stephen J., Martin Gleave, Antti Rannikko, et al.. (2023). 1766MO Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study. Annals of Oncology. 34. S955–S955. 1 indexed citations
7.
Vasudev, Naveen, Sarah Brown, Tom Waddell, et al.. (2021). LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). Annals of Oncology. 32. S1304–S1305. 4 indexed citations
8.
Choueiri, Toni K., James Larkin, Sumanta K. Pal, et al.. (2021). Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open. 6(3). 100101–100101. 34 indexed citations
9.
10.
Ramesh, Janani, et al.. (2019). Autophagy Intertwines with Different Diseases—Recent Strategies for Therapeutic Approaches. SHILAP Revista de lepidopterología. 7(1). 15–15. 20 indexed citations
11.
Venugopal, B., et al.. (2012). Isolation and identification of Candida albicans to produce in house helicase for PCR. Jurnal Natural (Faculty of Mathematics and Natural Science, Syiah Kuala University). 2(1).
12.
Venugopal, B. & T.R. Jeffry Evans. (2011). Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics. Current Medicinal Chemistry. 18(11). 1658–1671. 84 indexed citations
13.
Baird, Richard D., B. Venugopal, Montserrat Blanco-Codesido, et al.. (2011). A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.. Journal of Clinical Oncology. 29(15_suppl). 3024–3024. 1 indexed citations
14.
Curcio‐Morelli, Cyntia, Florie A. Charles, Matthew C. Micsenyi, et al.. (2010). Macroautophagy is defective in mucolipin-1-deficient mouse neurons. Neurobiology of Disease. 40(2). 370–377. 84 indexed citations
15.
Venugopal, B., John C. Kennedy, Cyntia Curcio‐Morelli, et al.. (2008). Chaperone‐mediated autophagy is defective in mucolipidosis type IV. Journal of Cellular Physiology. 219(2). 344–353. 95 indexed citations
16.
Venugopal, B., Marsha F. Browning, Cyntia Curcio‐Morelli, et al.. (2007). Neurologic, Gastric, and Opthalmologic Pathologies in a Murine Model of Mucolipidosis Type IV. The American Journal of Human Genetics. 81(5). 1070–1083. 116 indexed citations
17.
Bhattacharjee, M, B. Venugopal, K. T. Wong, & Yu‐ichi Goto. (2006). Mitochondrial Disorder, Diabetes Mellitus, and Findings in Three Muscles, Including the Heart. Ultrastructural Pathology. 30(6). 481–487. 7 indexed citations
18.
Yuasa, Takeshi, Ayumi Takakura, Bradley M. Denker, B. Venugopal, & Jing Zhou. (2004). Polycystin-1L2 is a novel G-protein-binding protein. Genomics. 84(1). 126–138. 42 indexed citations
19.
Yuasa, Takeshi, B. Venugopal, Stanislawa Weremowicz, et al.. (2002). The Sequence, Expression, and Chromosomal Localization of a Novel Polycystic Kidney Disease 1–Like Gene, PKD1L1 , in Human. Genomics. 79(3). 376–386. 39 indexed citations
20.
Luckey, T. D. & B. Venugopal. (1978). Chemical toxicity of metals and metalloids. Plenum Press eBooks. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhixian Hu Breakdown of academic impact, for papers by Cinzia Bottino Breakdown of academic impact, for papers by Germano Baj Breakdown of academic impact, for papers by Carolin Thomas Breakdown of academic impact, for papers by Li Dong Breakdown of academic impact, for papers by Kiyoshi Inageda Breakdown of academic impact, for papers by Hasan Mahmud Breakdown of academic impact, for papers by Manfred Wirth Breakdown of academic impact, for papers by Mei Liang Breakdown of academic impact, for papers by Luca Troncone
Rankless by CCL
2026